A COMAPRATIVE STUDY ON THE CLINICAL EFFECTIVENESS AND SAFETY BETWERN BILASTINE 40MG VS LEVOCETIRIZINE 1OMG IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: A OPEN LABEL, PARALLEL GROUP, BLINDED END POINT ASSESSMENT RANDOMISED CONTROL TRIAL - NI

Rajendra institute of medical sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年5月27日

试验速览

暂无简介。

•i. Patients with documented history of Chronic urticaria occurring >3 times/week for 8 weeks and an individual urticaria severity score of >2 for two urticaria symptoms for >3 days during the last 7 days screening period on the first visit day in OPD without any known inducible factor or definite cause.
•ii. Both sex.
•iii. Patients who give their informed written consent.

•i. Pregnant and lactating women.
•ii. Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.).
•iii. Any other prediagnosed systemic disease (eg. liver or kidney disorder).
•iv. Patients on any other form of treatment for any systemic diseases.
•v. Patients having prediagnosed Psychological conditions.
•vi. Patients with any form of inducible urticaria, known type of HS1, hereditary angioedema, known c1 esterase deficiency, urticaria associated with any malignancy or after acute or chronic infections
•vii. Patients having prediagnosed allergy to either of the study medications.
•viii. Patients working in night shifts or likely to change the usual sleep/wake cycle, those driving automobiles.
•ix. Patient’s participation in a clinical trial in the last 3 months.

发起方